About
Technology
Issues
FAQ
Links
Official Page
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.